ABT

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Abbott Laboratories

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.
CEO
Robert Ford
Employees
109000
Headquarters

100 Abbott Park Rd
Abbott Park, Illinois 60064-3500
Phone: 12246676100
www.abbott.com

News

Republicans Seek Documents, Schedule Hearing Related To FDA''s Response To Baby-Formula Shortage
Mar 21, 2023 19:37pm

House Republicans are reportedly speeding up their scrutiny of the FDA and the White House''s handling of the baby formula shortage last year. The supply crunch hit the U.S. market when Abbott Laboratories (NYSE: ABT ), a significant supplier, closed its Sturgis, Michigan, plant due to bacterial infection. House Oversight and Accountability Committee Chairman James Comer (R., Ky.) and Rep. Lisa McClain (R., Mich.), who leads its panel on healthcare, asked the FDA to submit all communications between the agency, White House staff, and the Health and Human Services Department … Full story available on Benzinga.com


Source:Benzinga
Abbott Labs: Steadily Getting Back To Normal
Mar 20, 2023 15:10pm

Abbott has had a crazy couple of years, with a formula recall and a COVID testing boom. Find out why I rate ABT stock a hold.


Source:Seeking Alpha
Abbott Laboratories Stock: A Dividend King At A Discount (NYSE:ABT)
Mar 20, 2023 08:46am

Abbott comes with a decent dividend yield and sustainable dividend growth backed by a wide-moat business model. Read why ABT stock is a Buy.


Source:Seeking Alpha
Protein Supplements Global Market Report 2023
Mar 08, 2023 13:23pm

Major players in the protein supplements market are GlaxoSmithKline (GSK), Glanbia PLC, ABBOTT LABORATORIES (ABBOTT), Amway Corporation, Herbalife International of America, Inc., PepsiCo, AMCO Proteins, QuestNutrition, GNC Holdings, Maker Nutrition LLC, SUPPLEFORM, Vitaco Health Limited, Garden of Life, Melaleuca Inc. Major players in the protein supplements market are GlaxoSmithKline (GSK), Glanbia PLC, ABBOTT LABORATORIES (ABBOTT), Amway Corporation, Herbalife International of America, Inc., PepsiCo, AMCO Proteins, QuestNutrition, GNC Holdings, Maker Nutrition LLC, SUPPLEFORM, Vitaco Health Limited, Garden of Life, Melaleuca Inc.


Source:GlobeNewswire
Abbott Laboratories (ABT) Looks Set To Grow At A Great Clip In 2023
Mar 07, 2023 13:00pm

Abbott Laboratories (NYSE:ABT) has a beta value of 0.67 and has seen 4.8 million shares traded in the last trading session. The company, currently valued at $175.46B, closed the last trade at $102.75 per share which meant it lost -$1.7 on the day or -1.63% during that session. The ABT stock price is -21.03% off … Abbott Laboratories (ABT) Looks Set To Grow At A Great Clip In 2023 Read More »


Source:Marketing Sentinel
Abbott Labs on target for all-EV fleet in 2023
Mar 07, 2023 11:40am

Abbott Laboratories is on target to switch its 475-strong UK car fleet to fully electric vehicles during 2023 with the help of Arval UK. Les Muggeridge, … Read More » The post Abbott Labs on target for all-EV fleet in 2023 appeared first on Fleet World .


Source:Fleet World Group
3 Health Care Stocks to Buy in a Heartbeat
Mar 07, 2023 08:57am

The healthcare industry is expanding, fueled by the increasing demand and advancements such as personalized medicines and telehealth. Hence, fundamentally strong healthcare stocks Abbott Laboratories (ABT), Centene (CNC), and McKesson…


Source:Entrepreneur
7 Dividend Kings to Buy for an Uncertain Market Environment
Mar 06, 2023 21:51pm

Though the term dividend aristocrats generate plenty of interest for the underlying elite status, another even more rarefied category exists called dividend kings to buy. Rather than 25 years of consecutive payout growth, the kings command at least 50 years. As we head into uncertain times, investors should pay close attention to this rare group of enterprises. Fundamentally, of course, companies that can afford to provide passive income to their stakeholders tend to be deeply established businesses. Should unexpected turbulence hit the market, they’re likelier to ride out the turmoil compared to growth-centric organizations. Therefore, dividend kings to buy deserve serious consideration for your portfolio. In addition, these elites of elite firms will want to keep the trend going at any cost. Naturally, you don’t want to be the person responsible for a 50-plus-year track record being broken. Thus, you’re in reasonably good hands with these dividend kings to buy. ABBV AbbVie $155.28 CL Colgate-Palmolive $73.29 PG Procter & Gamble $140.35 NWN Northwest Natural $47.41 KO Coca-Cola $60.36 SYY SYSCO $76.35 JNJ Johnson & Johnson $155.56 AbbVie (ABBV) Source: Sisacorn / Shutterstock.com A top-flight pharmaceutical firm, AbbVie (NYSE: ABBV ) ranks among the most intriguing dividend kings to buy.


Source:InvestorPlace
ABBOTT LABORATORIES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Abbott Laboratories - ABT
Mar 04, 2023 00:29am

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Abbott Laboratories (NYSE: ABT). In early 2022, the Company’s Sturgis, Michigan facility, was the subject of inspections by the U.S. Food and Drug Administration (“FDA”) that yielded several positive contamination results for the Cronobacter sakazakii bacteria, linked to infant illn


Source:Business Wire
Why Abbott Laboratories Stock Bumped Higher Today
Feb 28, 2023 23:30pm

The company''s specialized heart care products appear to prove their value in clinical testing.


Source:The Motley Fool
Better Buy: Abbott Laboratories or DexCom Stock?
Feb 24, 2023 14:45pm

Both stocks should benefit from the growth in diabetes care.


Source:The Motley Fool
Why Abbott Laboratories Stock Sank Today
Feb 22, 2023 23:07pm

The company''s glucose monitoring business might come under some serious pressure.


Source:The Motley Fool
Apple makes major progress on no-prick blood glucose tracking
Feb 22, 2023 19:02pm

Abbott Labs'' stock fell more than 3% as the markets reacted to hearing news of the tech giant''s secret moonshot project.


Source:Crain''s Chicago
Apple makes major progress on no-prick blood glucose tracking for its watch
Feb 22, 2023 18:16pm

California: Apple Inc. has a moonshot-style project underway that dates back to the Steve Jobs era: noninvasive and continuous blood glucose monitoring.

The goal of this secret endeavor - dubbed E5 - is to measure how much glucose is in someone’s body without needing to prick the skin for blood. After hitting major milestones recently, the company now believes it could eventually bring glucose monitoring to market, according to people familiar with the effort.

If perfected, such a breakthrough would be a boon to diabetics and help cement Apple as a powerhouse in health care. Adding the monitoring system to the Apple Watch, the ultimate goal, would also make that device an essential item for millions of diabetics around the world.

There’s still years of work ahead, but the move could upend a multibillion-dollar industry. Roughly 1 in 10 Americans have diabetes, and they typically rely on a device that pokes the skin for a blood sample. There are also patches from Dexcom Inc. and Abbott Laboratories that are inserted into the skin but need to be replaced about every two weeks.

Apple is taking a different approach, using a chip technology known as silicon photonics and a measurement process called optical absorption spectroscopy.


Source:The Peninsula Qatar
Abbott faces SEC and FTC investigation over infant formula operations
Feb 21, 2023 21:54pm

Abbott Laboratories is facing investigations from the Securities and Exchange Commission and Federal Trade Commission over its infant formula operation, marking the latest in a series of inquiries into the monthslong shutdown of a Michigan formula plant last year that kick-started a nationwide formula shortage.


Source:Washington Examiner
Abbott slips as govt. scrutiny over baby formula shortage tightens
Feb 21, 2023 20:01pm

Abbott Laboratories lost ~3% on Tuesday after disclosing that the SEC and Federal Trade Commission ((FTC)) are investigating its baby formula unit. Read the full story here.


Source:Seeking Alpha
New filing by ABBOTT LABORATORIES EMPLOYEE POLITICAL ACTION COMMITTEE
Feb 20, 2023 19:55pm

The ABBOTT LABORATORIES EMPLOYEE POLITICAL ACTION COMMITTEE successfully filed their F3XN FEBRUARY MONTHLY with the coverage period of 01/01/2023 to 01/31/2023 and a confirmation ID of FEC-1690175 *********CommitteeId: C00040279 | FilingId: 1690175 | FormType: F3XN | CoverageFrom: 01/01/2023 | CoverageThrough: 01/31/2023 | ReportType: FEBRUARY MONTHLY*********


Source:The FEC
Abbott Laboratories faces SEC investigation over baby formula after factory shutdown
Feb 20, 2023 19:12pm

The Securities and Exchange Commission (SEC) and the Federal Trade Commission (FTC) are launching investigations into the formula business at Abbott Laboratories. The recall of their Similac products in 2022, which led to the shutdown of their Michigan factory and formula shortages across the U.S., was sparked by the deaths of two infants who had taken the product.


Source:New York Daily News
Hypolipidemics Global Market Report 2023
Feb 20, 2023 16:41pm

Major players in the hypolipidemic drugs market are Abbott Laboratories Limited, Apotex Fermentation Inc., Biocon Limited, Cadila Healthcare Limited, Chunghwa Chem Syn& Biotech Co. Ltd, Concord Biotech Limited, Croda Europe Limited Leek, Daiichi Sankyo Company Limited, Dr. Major players in the hypolipidemic drugs market are Abbott Laboratories Limited, Apotex Fermentation Inc., Biocon Limited, Cadila Healthcare Limited, Chunghwa Chem Syn& Biotech Co. Ltd, Concord Biotech Limited, Croda Europe Limited Leek, Daiichi Sankyo Company Limited, Dr.


Source:GlobeNewswire
Abbott (NYSE:ABT) at High Legal Risk, According to SEC Report
Feb 20, 2023 09:01am

Abbott Laboratories’ (NYSE:ABT) infant formula business is still on the radar of regulators. The company’s recent SEC filing reveals that the Secur…


Source:TipRanks
Abbott gets FTC notice for information on infant formula products
Feb 18, 2023 01:32am

Abbott Laboratories said on Friday it received a civil investigative demand in January from the Federal Trade Commission related to a probe of the companies participating in bids for women, infants and children formula contracts.


Source:Reuters
Abbott Laboratories faces another FTC investigation over baby formula shortage
Feb 18, 2023 00:44am

Last month, Abbott received a civil investigative demand from the US FTC seeking information in connection with its probe of companies that participate in bids for formula contracts


Source:Livemint
Abbott Laboratories under SEC and FTC investigation over baby-formula business
Feb 17, 2023 23:36pm

The Securities and Exchange Commission and Federal Trade Commission are investigating Abbott Laboratories'' baby-formula business, the company said.


Source:MarketWatch
Abbott Faces a Second FTC Investigation Over Baby Formula Shortage - BNN Bloomberg
Feb 17, 2023 22:10pm

Abbott Laboratories is now facing a second probe into its role in a baby formula shortage last year that left millions of American families scrambling for vital nutrition products.


Source:BNN Bloomberg
Abbott Laboratories declares $0.51 dividend
Feb 17, 2023 17:28pm

Abbott Laboratories (ABT) declares $0.51/share quarterly dividend, in line with previous.


Source:Seeking Alpha
Cervical Cancer Diagnostics Global Market Report 2023
Feb 16, 2023 15:01pm

Major players in the cervical cancer diagnostics market are Abbott Laboratories, Becton, Dickinson and Co, Bio-Rad Laboratories Inc, F. Hoffmann-La Roche Ltd, Hologic Inc, QIAGEN NV, Quest Diagnostics Inc, Siemens Healthineers AG, Zilico, and Guided Therapeutics. Major players in the cervical cancer diagnostics market are Abbott Laboratories, Becton, Dickinson and Co, Bio-Rad Laboratories Inc, F. Hoffmann-La Roche Ltd, Hologic Inc, QIAGEN NV, Quest Diagnostics Inc, Siemens Healthineers AG, Zilico, and Guided Therapeutics.


Source:GlobeNewswire
Abbott Acquires Cardiovascular Systems: Key Takeaways For Investors
Feb 15, 2023 21:57pm

Abbott Laboratories expands its cardiovascular pipeline with its acquisition of Cardiovascular Systems, Inc. Click here for our take on what this means for ABT.


Source:Seeking Alpha
Abbott Laboratories will acquire Minnesota firm in deal worth $890 million
Feb 14, 2023 17:27pm

The deal for Minnesota-based Cardiovascular Systems is expected to improve Abbott''s portfolio of devices that treat vascular disease.


Source:Business Journals
Will Abbott Laboratories Remain A Top Dividend Aristocrat Stock? (NYSE:ABT)
Feb 14, 2023 16:49pm

Abbott Laboratories has been growing its dividends for over half a century and is one of only 37 US stocks to do so. See if ABT can continue to service the dividend.


Source:Seeking Alpha
The 7 Most Undervalued Dividend Aristocrats to Buy
Feb 13, 2023 22:42pm

If there’s anything better than having at least some exposure to passive income-providing enterprises, it’s loading the boat on the most undervalued dividend aristocrats to buy. Per Investopedia, “[d]ividend aristocrats are stocks of companies that have raised their dividends for at least 25 consecutive years .” Several of these enterprises have raised them for far longer, providing confidence for investors. Fundamentally, the most undervalued dividend aristocrats may come in hand this year due to lingering uncertainties. While speculation about a gradual return to normal lift equities for the year so far, questions started to pop up. In particular, a robust labor market implies that the Federal Reserve may still need to raise rates significantly. Plus, we have geopolitical tensions rising throughout the world, sending jitters into the financial system. While the most undervalued dividend aristocrats don’t provide perfect mitigation, they offer significant insulation. Below are seven ideas with analyst support to consider.


Source:InvestorPlace
Dow Jumps 250 Points; US Jobless Claims Increase Last Week
Feb 09, 2023 15:42pm

U.S. stocks traded higher this morning, with the Dow Jones jumping around 250 points on Thursday. The Dow traded up 0.75% to 34,204.99 while the NASDAQ rose 1.15% to 12,047.28. The S&P 500 also rose, gaining, 0.75% to 4,148.69. Check This Out: Amazon, Tesla And 2 Other Stocks Insiders Are Selling Leading and Lagging Sectors Health care shares rose by 0.2% on Thursday. Meanwhile, top gainers in the sector included Scilex Holding Company (NASDAQ: SCLX ), up 13%, and INmune Bio, Inc. (NASDAQ: INMB ), up 11%. In trading on Thursday, communication services shares dipped by 4.1%. Top Headline US initial jobless climbed to 196,000 in the week ending February 4, compared to the prior week''s nine-month low of 183,000. Equities Trading UP Cardiovascular Systems, Inc. (NASDAQ: CSII ) shares shot up 48% to $19.73 following Q2 results. Abbott Laboratories agreed to acquire Cardiovascular Systems for $20 per share for an equity value of approximately … Full story available on Benzinga.com


Source:Benzinga
Abbott to Acquire Cardiovascular Systems
Feb 09, 2023 15:25pm

Abbott (NYSE: ABT), acquired Cardiovascular Systems, a St. Paul, MN-based medical device company. Under terms of the agreement, CSI stockholders will receive $20 per common share at a total expected equity value of approximately $890 million. With the acquisition, Abbott will gain an innovative, complementary solution in treating vascular disease through CSI’s atherectomy system, which prepares vessels for angioplasty […] The post Abbott to Acquire Cardiovascular Systems appeared first on FinSMEs .


Source:FinSMEs
CSII stock jumps as Abbott agrees to acquire for $20/share (NYSE:ABT)
Feb 09, 2023 03:33am

Abbott Laboratories (ABT) has signed an agreement to acquire heart device maker Cardiovascular Systems (CSII) for $20 per share in a transaction worth ~$890M. Read the full story here.


Source:Seeking Alpha
Abbott Labs buys cardio company for $890 million
Feb 08, 2023 23:29pm

The deal helps Abbott strengthen its cardiovascular portfolio, a growth area for the company.


Source:Crain''s Chicago
Baby Formula Blues Hit Abbott Laboratories Stock Hard in 2022. Can It Rebound in 2023?
Feb 07, 2023 16:05pm

The healthcare stock fell 22% last year.


Source:The Motley Fool
Abbott Laboratories - Consensus Indicates Potential 10.0% Upside - DirectorsTalk Interviews
Feb 06, 2023 10:30am

Abbott Laboratories - Consensus Indicates Potential 10.0% Upside


Source:DirectorsTalk
Abbott receives FDA, EMA authorizations for cardiac catheters (NYSE:ABT)
Feb 02, 2023 16:45pm

Abbott Laboratories (ABT) has launched its TactiFlex ablation catheter (sensor enabled) in Europe after receiving CE Mark.The company said that TactiFlex can reduce procedure…


Source:Seeking Alpha
Looking At Abbott Laboratories''s Recent Unusual Options Activity
Feb 01, 2023 18:18pm

Someone with a lot of money to spend has taken a bearish stance on Abbott Laboratories (NYSE: ABT ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don''t know. But when something this big happens with ABT, it often means somebody knows something is about to happen. So how do we know what this whale just did? Today, Benzinga ''s options scanner spotted 10 uncommon options trades for Abbott Laboratories. This isn''t normal. The overall sentiment of these big-money traders is split between 20% bullish and 80%, bearish. Out of all of the special options we uncovered, 2 are puts, for a total amount of $136,782, and 8 are calls, for a total amount of $646,849. What''s The Price Target? Taking into account the Volume and Open Interest on these … Full story available on Benzinga.com


Source:Benzinga
FDA to overhaul food safety division in wake of baby formula issues (NYSE:ABT)
Jan 31, 2023 17:28pm

The US FDA will reorganize its food safety division to consolidate several functions in the aftermath of 2022''s baby formula shortage to prevent a similar occurrence.


Source:Seeking Alpha
Abbott Laboratories: The 3 Issues That Will Define 2023 Performance (NYSE:ABT)
Jan 30, 2023 19:22pm

Three critical issues will dictate Abbott''s stock performance in 2023. Read why, after 2023, ABT may morph back into a company investors know and love.


Source:Seeking Alpha
Dividend Kings and Aristocrats List: 10 Biggest Stocks
Jan 30, 2023 19:00pm

In this article, we will discuss 10 biggest dividend kings and dividend aristocrats. If you want to read our detailed analysis of dividend stocks and their returns in the past, go directly to read Dividend Kings and Aristocrats List: 50 Biggest Stocks. 10. Abbott Laboratories (NYSE:ABT) Market Cap as of January 28: $191.7 billion Abbott […]


Source:Insider Monkey
Is Abbott Laboratories a Good Dividend Stock to Buy Now? | The Motley Fool
Jan 28, 2023 10:24am

At least four Wall Street banks recently raised their price targets for the healthcare giant.


Source:The Motley Fool
Abbott Says FDA Oks Proclaim XR Spinal Cord Stimulation System To Treat DPN
Jan 26, 2023 14:42pm

NORTH CHICAGO (dpa-AFX) - Abbott Laboratories, Inc. (ABT) announced Thursday that the U.S. Food and Drug Administration (FDA) has approved its Proclaim XR spinal cord stimulation (SCS) system to t…


Source:Finanz Nachrichten
Abbott wins FDA approval of Proclaim XR for diabetic peripheral neuropathy (NYSE:ABT)
Jan 26, 2023 14:26pm

The FDA has expanded the use of Abbott Laboratories'' (ABT) Proclaim XR spinal cord stimulation system to include diabetic peripheral neuropathy.


Source:Seeking Alpha
FDA food safety chief resigns after baby formula recall
Jan 26, 2023 13:51pm

The agency’s food division has been under fire from critics who say it was slow to respond to questions about safety at an Abbott Laboratories infant-formula manufacturing site in Sturgis, Mich.


Source:Crain''s Chicago
Abbott Labs PT Raised to $125 at Stifel
Jan 26, 2023 13:07pm

https://www.investing.com/news/pro/abbott-labs-pt-raised-to-125-at-stifel-432SI-2988916


Source:Investing.com
Abbott Laboratories (ABT) Q4 2022 Earnings Call Transcript | AlphaStreet
Jan 26, 2023 12:27pm

Abbott Laboratories (NYSE:ABT) Q4 2022 Earnings Call dated Jan. 25, 2023.


Source:AlphaStreet
Abbott Labs PT Raised to $125 at BTIG
Jan 26, 2023 11:28am

https://www.investing.com/news/pro/abbott-labs-pt-raised-to-125-at-btig-432SI-2988627


Source:Investing.com
Abbott Labs PT Raised to $123 at Raymond James
Jan 26, 2023 11:28am

https://www.investing.com/news/pro/abbott-labs-pt-raised-to-123-at-raymond-james-432SI-2988624


Source:Investing.com
Abbott Labs PT Raised to $132 at Bernstein
Jan 26, 2023 09:25am

https://www.investing.com/news/pro/abbott-labs-pt-raised-to-132-at-bernstein-432SI-2988511


Source:Investing.com
Why Abbott Laboratories Stock Got Whacked on Wednesday
Jan 25, 2023 22:29pm

Double beats for its latest quarter couldn''t keep the bears away from the company''s shares on Hump Day.


Source:The Motley Fool
Abbott Labs PT Raised to $107 at Wolfe Research
Jan 25, 2023 21:13pm

https://www.investing.com/news/pro/abbott-labs-pt-raised-to-107-at-wolfe-research-432SI-2988115


Source:Investing.com
Abbott Laboratories (ABT) Q4 2022 Earnings Call Transcript
Jan 25, 2023 18:00pm

Abbott Laboratories (NYSE:NYSE:ABT) Q4 2022 Earnings Conference Call January 25, 2023 9:00 AM ETCompany ParticipantsScott Leinenweber - Vice President, Investor RelationsRobert Ford -…


Source:Seeking Alpha
What''s Going On With Abbott Laboratories Stock Today?
Jan 25, 2023 17:30pm

Abbott Laboratories (NYSE: ABT ) shares are trading lower Wednesday in the wake of the company''s quarterly results . What Happened: Abbott said fourth-quarter revenue decreased 12% year-over-year to $10.1 billion, which beat average analyst estimates of $9.64 billion, according to Benzinga Pro . The company said its top-line results were negatively impacted by an expected year-over-year decline in COVID-19 testing-related sales. Abbott reported fourth-quarter earnings of $1.03 per share, which beat average estimates of 92 cents per share. Investors … Full story available on Benzinga.com


Source:Benzinga
Formula plant shutdown drags on Abbott Labs'' earnings
Jan 25, 2023 16:54pm

Lower demand for the company’s COVID tests also dampened fourth-quarter performance.


Source:Crain''s Chicago
Abbott Laboratories tops Q4 earnings
Jan 25, 2023 15:33pm

Yahoo Finance published this video item, entitled "Abbott Laboratories tops Q4 earnings" - below is their description.


Source:The Global Herald
Infographic: How Abbott Laboratories (ABT) performed in Q4 2022 financial results
Jan 25, 2023 14:56pm

Abbott Laboratories (NYSE: ABT) reported fourth quarter 2022 earnings results today. Net sales declined 12% year-over-year to $10.1 billion. Net earnings decreased 48% to $1 billion while EPS fell 47% […] The post Infographic: How Abbott Laboratories (ABT) performed in Q4 2022 financial results first appeared on AlphaStreet .


Source:AlphaStreet
Earnings Scheduled For January 25, 2023
Jan 25, 2023 09:30am

Companies Reporting Before The Bell • ASML Holding (NASDAQ: ASML ) is expected to report quarterly earnings at $4.45 per share on revenue of $6.50 billion. • Norfolk Southern (NYSE: NSC ) is projected to report quarterly earnings at $3.44 per share on revenue of $3.20 billion. • Freeport-McMoRan (NYSE: FCX ) is estimated to report quarterly earnings at $0.43 per share on revenue of $5.42 billion. • Hess Midstream (NYSE: HESM ) is likely to report quarterly earnings at $0.54 per share on revenue of $327.86 million. • Popular (NASDAQ: BPOP ) is projected to report quarterly earnings at $2.62 per share on revenue of $565.86 million. • Progressive (NYSE: PGR ) is estimated to report quarterly earnings at $1.43 per share on revenue of $12.35 billion. • Hess (NYSE: HES ) is estimated to report quarterly earnings at $1.65 per share on revenue of $2.60 billion. • MarketAxess Holdings (NASDAQ: MKTX ) is estimated to report quarterly earnings at $1.56 per share on revenue of $176.92 million. • Textron (NYSE: TXT ) is likely to report quarterly earnings at $1.


Source:Benzinga
US stocks lower premarket with more earnings ahead
Jan 25, 2023 09:01am

Stock exchanges in the United States traded lower in the premarket on Wednesday as investors awaited more quarterly reports by major companies. AT&T, Abbott Laboratories and Boeing are set to rele…


Source:Breaking the News 24/7
Earnings Outlook For Abbott Laboratories
Jan 24, 2023 14:02pm

Abbott Laboratories (NYSE: ABT ) is set to give its latest quarterly earnings report on Wednesday, 2023-01-25. Here''s what investors need to know before the announcement. Analysts estimate that Abbott Laboratories will report an earnings per share (EPS) of $0.92. Abbott Laboratories bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com


Source:Benzinga